Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer
Therapeutic Advances in Medical Oncology · 2026-08 · 18
DOI: 10.1177/17588359261477589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 20.08.2026. Verfasst von Xiujuan Gui und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-s…. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GuangDong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have revolutionized the treatment for HER2-positive and HER2-low metastatic breast cancer (MBC). However, the comparative efficacy, safety, and molecular predictors of response to various anti-HER2 ADCs remain limited.
Objectives
To evaluate real-world clinical outcomes, safety profiles, and genomic alterations associated with response to anti-HER2 ADCs in patients with HER2-positive or HER2-low MBC.
Design
Retrospective single-center cohort study.
Methods
Patients with HER2-positive or HER2-low MBC who received anti-HER2 ADCs (T-DXd, SHR-A1811, RC48, or T-DM1) between September 1, 2020, and September 1, 2024, were enrolled. Progression-free survival (PFS), overall survival, objective response rate (ORR), and safety were assessed. Targeted next-generation sequencing was performed to identify genomic correlates of response.
Results
A total of 322 patients were included, comprising 183 HER2-positive and 139 HER2-low cases. The ORR in the HER2-positive group and the HER2-low group were 32.8% versus 20.8%, respectively, and median PFS were 9.9 months versus 4.1 months. Median PFS in the T-DXd, SHR-A1811, RC48, and T-DM1 groups were 9.3 months, 25.8 months, 3.2 months, and 7.6 months, respectively (p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Phase I Clinical Trial Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
ORCID-Profile: Haizhu Chen, Herui Yao, Linxiaoxiao Ding
Förderung
- GuangDong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
Zitieren
APA
Gui, X., Chen, H., Zhao, J., Lai, H., Luo, S., Chai, J., Cai, Y., Wu, W., Zeng, Y., Chen, M., Wang, Y., Yao, H., & Ding, L. (2026). Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261477589
Vancouver
Gui X, Chen H, Zhao J, Lai H, Luo S, Chai J, et al. Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261477589
BibTeX
@article{Gui2026,
author = {Gui, Xiujuan and Chen, Haizhu and Zhao, Jianli and Lai, Hongna and Luo, Simin and Chai, Jie and Cai, Yangyang and Wu, Wenjing and Zeng, Yinduo and Chen, Maojian and Wang, Ying and Yao, Herui and Ding, Linxiaoxiao},
title = {Clinical outcomes and genomic landscape of anti-HER2 antibody-drug conjugates in HER2-positive and HER2-low metastatic breast cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261477589}
}
EUVIMED